Skip to main content
IONS
NASDAQ Life Sciences

Ionis Partner GSK Reports Positive Phase 3 Results for Bepirovirsen in Chronic Hepatitis B

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$83.06
Mkt Cap
$13.471B
52W Low
$23.95
52W High
$86.15
52W Position info
247% above low
Off High info
3.6% below high
Rel. Volume info
1.7× avg
Market data snapshot near publication time

IONS has more than doubled off its 52-week low of $23.95.

Summary

Ionis Pharmaceuticals announced that its partner GSK reported positive topline results from two pivotal Phase 3 studies for bepirovirsen, an investigational treatment for chronic hepatitis B, meeting primary endpoints and demonstrating a statistically significant functional cure rate.


Key Events · Product Development and Regulatory · IONS

  • Positive Phase 3 Results

    GSK, Ionis' partner, announced positive topline results from two pivotal Phase 3 studies (B-Well 1 and B-Well 2) for bepirovirsen in chronic hepatitis B (CHB).

  • Met Primary Endpoint

    Both studies met their primary endpoint, demonstrating a statistically significant and clinically meaningful functional cure rate for bepirovirsen.

  • Significant Market Opportunity

    Bepirovirsen targets CHB, a major global health challenge affecting over 250 million people, with potential to be the first finite, six-month therapeutic option.

  • Regulatory Designations

    The drug has received Fast Track designation from the US FDA, Breakthrough Therapy designation in China, and SENKU designation in Japan, highlighting its innovation and unmet need.


Analysis · IONS · Life Sciences

This filing is highly significant as it announces positive Phase 3 results for bepirovirsen, a potential first-in-class treatment for chronic hepatitis B, a disease affecting over 250 million people globally with limited current cure options. The successful trial outcomes, coupled with existing Fast Track and Breakthrough Therapy designations, significantly de-risk the program and pave the way for global regulatory submissions. For Ionis, this represents a substantial future revenue stream through milestone payments and tiered royalties, reinforcing the value of its antisense oligonucleotide technology and its collaborative development model. This positive readout also sets a strong precedent as the first of several anticipated Phase 3 results for Ionis this year.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, IONS was trading at $83.06 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $13.5B. The 52-week trading range was $23.95 to $86.15. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

IONS - Latest Insights

IONS
Nov 17, 2026, 4:45 PM EST
Source: BusinessWire
Importance Score:
7
Price at Filing: $26.93
Real-time Price: $26.76 info
Change: -$0.170 (-0.63%) info
Market Cap: $4.427B info
IONS
Nov 17, 2026, 3:03 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $28.02
Real-time Price: $26.76 info
Change: -$1.26 (-4%) info
Market Cap: $4.427B info
IONS
Nov 10, 2026, 3:00 AM EST
Source: Wiseek News
Importance Score:
7
Price at Filing: $31.17
Real-time Price: $26.76 info
Change: -$4.41 (-14%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 11:01 AM EST
Source: Seeking Alpha
Importance Score:
8
Price at Filing: $28.67
Real-time Price: $26.76 info
Change: -$1.90 (-7%) info
Market Cap: $4.427B info
IONS
Nov 09, 2026, 8:33 AM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $31.50
Real-time Price: $26.76 info
Change: -$4.74 (-15%) info
Market Cap: $4.427B info